Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Identifieur interne : 002E08 ( PubMed/Corpus ); précédent : 002E07; suivant : 002E09Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
Auteurs : Konstantinos Karmiris ; Peter Bossuyt ; Dario Sorrentino ; Tom Moreels ; Antonella Scarcelli ; Jesus Legido ; Iris Dotan ; Graham D. Naismith ; Airi Jussila ; Jan C. Preiss ; Wolfgang Kruis ; Andy C Y. Li ; Guillaume Bouguen ; Henit Yanai ; Flavio Steinwurz ; Konstantinos H. Katsanos ; Kavitha Subramaniam ; Dino Tarabar ; Ioannis V. Zaganas ; Shomron Ben-HorinSource :
- Journal of Crohn's & colitis [ 1876-4479 ] ; 2015.
English descriptors
- KwdEn :
- Adalimumab (therapeutic use), Adult, Anti-Inflammatory Agents, Non-Steroidal (therapeutic use), Azathioprine (therapeutic use), Cerebrovascular Disorders (diagnosis), Cerebrovascular Disorders (etiology), Certolizumab Pegol (therapeutic use), Colitis, Ulcerative (complications), Colitis, Ulcerative (drug therapy), Crohn Disease (complications), Crohn Disease (drug therapy), Drug Therapy, Combination, Female, Humans, Immunosuppressive Agents (therapeutic use), Infliximab (therapeutic use), Male, Methotrexate (therapeutic use), Middle Aged, Rare Diseases (diagnosis), Rare Diseases (etiology), Retreatment, Retrospective Studies, Tumor Necrosis Factor-alpha (antagonists & inhibitors), Young Adult.
- MESH :
- chemical , antagonists & inhibitors : Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Adalimumab, Anti-Inflammatory Agents, Non-Steroidal, Azathioprine, Certolizumab Pegol, Immunosuppressive Agents, Infliximab, Methotrexate.
- complications : Colitis, Ulcerative, Crohn Disease.
- diagnosis : Cerebrovascular Disorders, Rare Diseases.
- drug therapy : Colitis, Ulcerative, Crohn Disease.
- etiology : Cerebrovascular Disorders, Rare Diseases.
- Adult, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Retreatment, Retrospective Studies, Young Adult.
Abstract
Cerebrovascular accidents [CVA] have rarely been reported in inflammatory bowel disease [IBD] patients treated with anti-tumour necrosis alpha [anti-TNF alpha] agents. Our aim here was to describe the clinical course of CVA in these patients.
DOI: 10.1093/ecco-jcc/jjv042
PubMed: 25740813
Links to Exploration step
pubmed:25740813Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.</title><author><name sortKey="Karmiris, Konstantinos" sort="Karmiris, Konstantinos" uniqKey="Karmiris K" first="Konstantinos" last="Karmiris">Konstantinos Karmiris</name><affiliation><nlm:affiliation>Department of Gastroenterology, Venizeleio General Hospital, Heraklion, Crete, Greece kkarmiris@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Bossuyt, Peter" sort="Bossuyt, Peter" uniqKey="Bossuyt P" first="Peter" last="Bossuyt">Peter Bossuyt</name><affiliation><nlm:affiliation>Imelda GI Clinical Research Center, Bonheiden, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Sorrentino, Dario" sort="Sorrentino, Dario" uniqKey="Sorrentino D" first="Dario" last="Sorrentino">Dario Sorrentino</name><affiliation><nlm:affiliation>IBD Center, Virginia Tech-Carilion School of Medicine, Roanoke, VA, USA and Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, Udine, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Moreels, Tom" sort="Moreels, Tom" uniqKey="Moreels T" first="Tom" last="Moreels">Tom Moreels</name><affiliation><nlm:affiliation>Department of Hepato-gastroenterology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Scarcelli, Antonella" sort="Scarcelli, Antonella" uniqKey="Scarcelli A" first="Antonella" last="Scarcelli">Antonella Scarcelli</name><affiliation><nlm:affiliation>Department of Gastroenterology, Azienda University Hospital, Policlinico di Modena, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Legido, Jesus" sort="Legido, Jesus" uniqKey="Legido J" first="Jesus" last="Legido">Jesus Legido</name><affiliation><nlm:affiliation>Gastroenterology Unit, Segovia General Hospital, Segovia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Dotan, Iris" sort="Dotan, Iris" uniqKey="Dotan I" first="Iris" last="Dotan">Iris Dotan</name><affiliation><nlm:affiliation>IBD Center, Department of Gastroenterology and Liver Diseases and the Sackler School of Medicine, Sourasky Medical Center, Tel Aviv, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Naismith, Graham D" sort="Naismith, Graham D" uniqKey="Naismith G" first="Graham D" last="Naismith">Graham D. Naismith</name><affiliation><nlm:affiliation>Department of Gastroenterology, Paisley RAH, Glasgow, Scotland.</nlm:affiliation></affiliation></author><author><name sortKey="Jussila, Airi" sort="Jussila, Airi" uniqKey="Jussila A" first="Airi" last="Jussila">Airi Jussila</name><affiliation><nlm:affiliation>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Preiss, Jan C" sort="Preiss, Jan C" uniqKey="Preiss J" first="Jan C" last="Preiss">Jan C. Preiss</name><affiliation><nlm:affiliation>Charité-Universitätsmedizin, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kruis, Wolfgang" sort="Kruis, Wolfgang" uniqKey="Kruis W" first="Wolfgang" last="Kruis">Wolfgang Kruis</name><affiliation><nlm:affiliation>Charité-Universitätsmedizin, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Andy C Y" sort="Li, Andy C Y" uniqKey="Li A" first="Andy C Y" last="Li">Andy C Y. Li</name><affiliation><nlm:affiliation>Department of Gastroenterology, Western Sussex Hospitals NHSFT, Worthing, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bouguen, Guillaume" sort="Bouguen, Guillaume" uniqKey="Bouguen G" first="Guillaume" last="Bouguen">Guillaume Bouguen</name><affiliation><nlm:affiliation>Department of Gastroenterology, University Hospital Pontchaillou, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Yanai, Henit" sort="Yanai, Henit" uniqKey="Yanai H" first="Henit" last="Yanai">Henit Yanai</name><affiliation><nlm:affiliation>Gastroenterology Unit, Segovia General Hospital, Segovia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Steinwurz, Flavio" sort="Steinwurz, Flavio" uniqKey="Steinwurz F" first="Flavio" last="Steinwurz">Flavio Steinwurz</name><affiliation><nlm:affiliation>IBD Unit, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Katsanos, Konstantinos H" sort="Katsanos, Konstantinos H" uniqKey="Katsanos K" first="Konstantinos H" last="Katsanos">Konstantinos H. Katsanos</name><affiliation><nlm:affiliation>Division of Gastroenterology, University Hospital of Ioannina, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Subramaniam, Kavitha" sort="Subramaniam, Kavitha" uniqKey="Subramaniam K" first="Kavitha" last="Subramaniam">Kavitha Subramaniam</name><affiliation><nlm:affiliation>Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Tarabar, Dino" sort="Tarabar, Dino" uniqKey="Tarabar D" first="Dino" last="Tarabar">Dino Tarabar</name><affiliation><nlm:affiliation>Department of Gastroenterology, MMA Belgrade, Serbia.</nlm:affiliation></affiliation></author><author><name sortKey="Zaganas, Ioannis V" sort="Zaganas, Ioannis V" uniqKey="Zaganas I" first="Ioannis V" last="Zaganas">Ioannis V. Zaganas</name><affiliation><nlm:affiliation>Department of Neurology, University Hospital of Heraklion, Heraklion, Crete, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Ben Horin, Shomron" sort="Ben Horin, Shomron" uniqKey="Ben Horin S" first="Shomron" last="Ben-Horin">Shomron Ben-Horin</name><affiliation><nlm:affiliation>Department of Gastroenterology, Sheba Medical Center, Tel-Aviv University, Tel-Aviv, Israel.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25740813</idno><idno type="pmid">25740813</idno><idno type="doi">10.1093/ecco-jcc/jjv042</idno><idno type="wicri:Area/PubMed/Corpus">002E08</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E08</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.</title><author><name sortKey="Karmiris, Konstantinos" sort="Karmiris, Konstantinos" uniqKey="Karmiris K" first="Konstantinos" last="Karmiris">Konstantinos Karmiris</name><affiliation><nlm:affiliation>Department of Gastroenterology, Venizeleio General Hospital, Heraklion, Crete, Greece kkarmiris@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Bossuyt, Peter" sort="Bossuyt, Peter" uniqKey="Bossuyt P" first="Peter" last="Bossuyt">Peter Bossuyt</name><affiliation><nlm:affiliation>Imelda GI Clinical Research Center, Bonheiden, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Sorrentino, Dario" sort="Sorrentino, Dario" uniqKey="Sorrentino D" first="Dario" last="Sorrentino">Dario Sorrentino</name><affiliation><nlm:affiliation>IBD Center, Virginia Tech-Carilion School of Medicine, Roanoke, VA, USA and Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, Udine, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Moreels, Tom" sort="Moreels, Tom" uniqKey="Moreels T" first="Tom" last="Moreels">Tom Moreels</name><affiliation><nlm:affiliation>Department of Hepato-gastroenterology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.</nlm:affiliation></affiliation></author><author><name sortKey="Scarcelli, Antonella" sort="Scarcelli, Antonella" uniqKey="Scarcelli A" first="Antonella" last="Scarcelli">Antonella Scarcelli</name><affiliation><nlm:affiliation>Department of Gastroenterology, Azienda University Hospital, Policlinico di Modena, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Legido, Jesus" sort="Legido, Jesus" uniqKey="Legido J" first="Jesus" last="Legido">Jesus Legido</name><affiliation><nlm:affiliation>Gastroenterology Unit, Segovia General Hospital, Segovia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Dotan, Iris" sort="Dotan, Iris" uniqKey="Dotan I" first="Iris" last="Dotan">Iris Dotan</name><affiliation><nlm:affiliation>IBD Center, Department of Gastroenterology and Liver Diseases and the Sackler School of Medicine, Sourasky Medical Center, Tel Aviv, Israel.</nlm:affiliation></affiliation></author><author><name sortKey="Naismith, Graham D" sort="Naismith, Graham D" uniqKey="Naismith G" first="Graham D" last="Naismith">Graham D. Naismith</name><affiliation><nlm:affiliation>Department of Gastroenterology, Paisley RAH, Glasgow, Scotland.</nlm:affiliation></affiliation></author><author><name sortKey="Jussila, Airi" sort="Jussila, Airi" uniqKey="Jussila A" first="Airi" last="Jussila">Airi Jussila</name><affiliation><nlm:affiliation>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.</nlm:affiliation></affiliation></author><author><name sortKey="Preiss, Jan C" sort="Preiss, Jan C" uniqKey="Preiss J" first="Jan C" last="Preiss">Jan C. Preiss</name><affiliation><nlm:affiliation>Charité-Universitätsmedizin, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Kruis, Wolfgang" sort="Kruis, Wolfgang" uniqKey="Kruis W" first="Wolfgang" last="Kruis">Wolfgang Kruis</name><affiliation><nlm:affiliation>Charité-Universitätsmedizin, Berlin, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Li, Andy C Y" sort="Li, Andy C Y" uniqKey="Li A" first="Andy C Y" last="Li">Andy C Y. Li</name><affiliation><nlm:affiliation>Department of Gastroenterology, Western Sussex Hospitals NHSFT, Worthing, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bouguen, Guillaume" sort="Bouguen, Guillaume" uniqKey="Bouguen G" first="Guillaume" last="Bouguen">Guillaume Bouguen</name><affiliation><nlm:affiliation>Department of Gastroenterology, University Hospital Pontchaillou, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Yanai, Henit" sort="Yanai, Henit" uniqKey="Yanai H" first="Henit" last="Yanai">Henit Yanai</name><affiliation><nlm:affiliation>Gastroenterology Unit, Segovia General Hospital, Segovia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Steinwurz, Flavio" sort="Steinwurz, Flavio" uniqKey="Steinwurz F" first="Flavio" last="Steinwurz">Flavio Steinwurz</name><affiliation><nlm:affiliation>IBD Unit, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.</nlm:affiliation></affiliation></author><author><name sortKey="Katsanos, Konstantinos H" sort="Katsanos, Konstantinos H" uniqKey="Katsanos K" first="Konstantinos H" last="Katsanos">Konstantinos H. Katsanos</name><affiliation><nlm:affiliation>Division of Gastroenterology, University Hospital of Ioannina, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Subramaniam, Kavitha" sort="Subramaniam, Kavitha" uniqKey="Subramaniam K" first="Kavitha" last="Subramaniam">Kavitha Subramaniam</name><affiliation><nlm:affiliation>Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Tarabar, Dino" sort="Tarabar, Dino" uniqKey="Tarabar D" first="Dino" last="Tarabar">Dino Tarabar</name><affiliation><nlm:affiliation>Department of Gastroenterology, MMA Belgrade, Serbia.</nlm:affiliation></affiliation></author><author><name sortKey="Zaganas, Ioannis V" sort="Zaganas, Ioannis V" uniqKey="Zaganas I" first="Ioannis V" last="Zaganas">Ioannis V. Zaganas</name><affiliation><nlm:affiliation>Department of Neurology, University Hospital of Heraklion, Heraklion, Crete, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Ben Horin, Shomron" sort="Ben Horin, Shomron" uniqKey="Ben Horin S" first="Shomron" last="Ben-Horin">Shomron Ben-Horin</name><affiliation><nlm:affiliation>Department of Gastroenterology, Sheba Medical Center, Tel-Aviv University, Tel-Aviv, Israel.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Journal of Crohn's & colitis</title><idno type="eISSN">1876-4479</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adalimumab (therapeutic use)</term><term>Adult</term><term>Anti-Inflammatory Agents, Non-Steroidal (therapeutic use)</term><term>Azathioprine (therapeutic use)</term><term>Cerebrovascular Disorders (diagnosis)</term><term>Cerebrovascular Disorders (etiology)</term><term>Certolizumab Pegol (therapeutic use)</term><term>Colitis, Ulcerative (complications)</term><term>Colitis, Ulcerative (drug therapy)</term><term>Crohn Disease (complications)</term><term>Crohn Disease (drug therapy)</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Infliximab (therapeutic use)</term><term>Male</term><term>Methotrexate (therapeutic use)</term><term>Middle Aged</term><term>Rare Diseases (diagnosis)</term><term>Rare Diseases (etiology)</term><term>Retreatment</term><term>Retrospective Studies</term><term>Tumor Necrosis Factor-alpha (antagonists & inhibitors)</term><term>Young Adult</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adalimumab</term><term>Anti-Inflammatory Agents, Non-Steroidal</term><term>Azathioprine</term><term>Certolizumab Pegol</term><term>Immunosuppressive Agents</term><term>Infliximab</term><term>Methotrexate</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Colitis, Ulcerative</term><term>Crohn Disease</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Cerebrovascular Disorders</term><term>Rare Diseases</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Colitis, Ulcerative</term><term>Crohn Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cerebrovascular Disorders</term><term>Rare Diseases</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Retreatment</term><term>Retrospective Studies</term><term>Young Adult</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Cerebrovascular accidents [CVA] have rarely been reported in inflammatory bowel disease [IBD] patients treated with anti-tumour necrosis alpha [anti-TNF alpha] agents. Our aim here was to describe the clinical course of CVA in these patients.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25740813</PMID><DateCreated><Year>2015</Year><Month>04</Month><Day>29</Day></DateCreated><DateCompleted><Year>2016</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2016</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1876-4479</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of Crohn's & colitis</Title><ISOAbbreviation>J Crohns Colitis</ISOAbbreviation></Journal><ArticleTitle>Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.</ArticleTitle><Pagination><MedlinePgn>382-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/ecco-jcc/jjv042</ELocationID><Abstract><AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Cerebrovascular accidents [CVA] have rarely been reported in inflammatory bowel disease [IBD] patients treated with anti-tumour necrosis alpha [anti-TNF alpha] agents. Our aim here was to describe the clinical course of CVA in these patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a European Crohn's and Colitis Organisation [ECCO] retrospective observational study, performed as part of the CONFER [COllaborative Network For Exceptionally Rare case reports] project. A call to all ECCO members was made to report on IBD patients afflicted with CVA during treatment with anti-TNF alpha agents. Clinical data were recorded in a standardised case report form and analysed for event association with anti-TNF alpha treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 19 patients were identified from 16 centres: 14 had Crohn's disease, four ulcerative colitis and one IBD colitis unclassified [median age at diagnosis: 38.0 years, range: 18.6-62.5]. Patients received anti-TNF alpha for a median duration of 11.8 months [range: 0-62] at CVA onset; seven had previously been treated with at least one other anti-TNF alpha agent. Complete neurological recovery was observed in 16 patients. Anti-TNF alpha was discontinued in 16/19 patients. However, recurrent CVA or neurological deterioration was not observed in any of the 11 patients who received anti-TNF alpha after CVA [eight resumed after temporary cessation, three continued without interruption] for a median follow-up of 39.8 months [range: 5.6-98.2].</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These preliminary findings do not unequivocally indicate a causal role of anti-TNF alpha in CVA complicating IBD. Resuming or continuing anti-TNF alpha in IBD patients with CVA may be feasible and safe in selected cases, but careful weighing of IBD activity versus neurological status is prudent.</AbstractText><CopyrightInformation>Copyright © 2015 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karmiris</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Venizeleio General Hospital, Heraklion, Crete, Greece kkarmiris@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bossuyt</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Imelda GI Clinical Research Center, Bonheiden, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sorrentino</LastName><ForeName>Dario</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IBD Center, Virginia Tech-Carilion School of Medicine, Roanoke, VA, USA and Department of Clinical and Experimental Medical Sciences, University of Udine School of Medicine, Udine, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moreels</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Hepato-gastroenterology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scarcelli</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Azienda University Hospital, Policlinico di Modena, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legido</LastName><ForeName>Jesus</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Segovia General Hospital, Segovia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dotan</LastName><ForeName>Iris</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>IBD Center, Department of Gastroenterology and Liver Diseases and the Sackler School of Medicine, Sourasky Medical Center, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naismith</LastName><ForeName>Graham D</ForeName><Initials>GD</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Paisley RAH, Glasgow, Scotland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jussila</LastName><ForeName>Airi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Preiss</LastName><ForeName>Jan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Charité-Universitätsmedizin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kruis</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Charité-Universitätsmedizin, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Andy C Y</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Western Sussex Hospitals NHSFT, Worthing, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bouguen</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, University Hospital Pontchaillou, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yanai</LastName><ForeName>Henit</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gastroenterology Unit, Segovia General Hospital, Segovia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinwurz</LastName><ForeName>Flavio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>IBD Unit, Hospital Israelita Albert Einstein, Sao Paulo, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsanos</LastName><ForeName>Konstantinos H</ForeName><Initials>KH</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, University Hospital of Ioannina, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Subramaniam</LastName><ForeName>Kavitha</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Gastroenterology and Hepatology Unit, Canberra Hospital, Canberra, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarabar</LastName><ForeName>Dino</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, MMA Belgrade, Serbia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaganas</LastName><ForeName>Ioannis V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Hospital of Heraklion, Heraklion, Crete, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ben-Horin</LastName><ForeName>Shomron</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Gastroenterology, Sheba Medical Center, Tel-Aviv University, Tel-Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ECCO CONFER investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Crohns Colitis</MedlineTA><NlmUniqueID>101318676</NlmUniqueID><ISSNLinking>1873-9946</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>B72HH48FLU</RegistryNumber><NameOfSubstance UI="D000069285">Infliximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>FYS6T7F842</RegistryNumber><NameOfSubstance UI="D000068879">Adalimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>MRK240IY2L</RegistryNumber><NameOfSubstance UI="D001379">Azathioprine</NameOfSubstance></Chemical><Chemical><RegistryNumber>UMD07X179E</RegistryNumber><NameOfSubstance UI="D000068582">Certolizumab Pegol</NameOfSubstance></Chemical><Chemical><RegistryNumber>YL5FZ2Y5U1</RegistryNumber><NameOfSubstance UI="D008727">Methotrexate</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000068879" MajorTopicYN="N">Adalimumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="N">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001379" MajorTopicYN="N">Azathioprine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002561" MajorTopicYN="N">Cerebrovascular Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068582" MajorTopicYN="N">Certolizumab Pegol</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="N">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003424" MajorTopicYN="N">Crohn Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004359" MajorTopicYN="N">Drug Therapy, Combination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069285" MajorTopicYN="N">Infliximab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008727" MajorTopicYN="N">Methotrexate</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035583" MajorTopicYN="N">Rare Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019233" MajorTopicYN="N">Retreatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="Y">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cerebrovascular accidents</Keyword><Keyword MajorTopicYN="N">anti-TNF alpha agents</Keyword><Keyword MajorTopicYN="N">inflammatory bowel disease</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25740813</ArticleId><ArticleId IdType="pii">jjv042</ArticleId><ArticleId IdType="doi">10.1093/ecco-jcc/jjv042</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002E08 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002E08 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25740813
|texte= Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25740813" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |